Sign In
12 Nov 2008 17:01
ο»Ώ
Directors'Β Dealings
PuriCore DirectorsΒ Acquire Shares in the Company
MALVERN, PENNSYLVANIA, AND STAFFORD, UK, 12Β NovemberΒ 2008-PuriCore (LSE: PURI), the life sciences company focused on the control of infectious pathogens with its novel, safe antimicrobial technology, today announces thatΒ two Directors have recently purchased shares in the Company. OnΒ 11Β NovemberΒ 2008, GregΒ BoschΒ informed the Company he purchased sharesΒ on that date,Β and on 12 NovemberΒ 2008,Β Timothy AndersonΒ informed the Company heΒ purchased sharesΒ on this date. Mr.Β Anderson's purchase was made through Green Bay Enterprises, LLC, a family investment partnership. Further details of the purchases areΒ set out below:
|
Name |
Number of shares purchased |
Purchase Price of shares |
Total number of shares held |
% of issued share capital |
|
Greg Bosch |
300,000 |
9.38p |
500,000 |
0.23 |
|
Timothy Anderson |
100,000 |
9.13p |
100,000 |
Β 0.05 |
Enquiries:
|
Ben Brewerton |
Greg Bosch, CEO |
|
Susan Quigley |
Darren Weiss, VP Finance |
|
Financial Dynamics |
PuriCore |
|
+44 (0) 20 7831 3113 |
+1 484 321 2700 |
About PuriCore
PuriCore plc (LSE: PURI) is a life sciences company focused on developing and commercialising proprietary products that safely, effectively, and naturally kill contagious pathogens. PuriCore's technology provides a solution to a broad range of markets that depend upon controlling contamination, including food safety in retail and foodservice, medical device disinfection, wound therapy, and hospitality. The Company's proprietary technology mimics the human body's production of the natural antimicrobial hypochlorous acid, which is highly effective in killing bacteria, viruses, and fungal spores. Deploying hypochlorous acid solutions as soaks, sprays, mists, and in other forms, PuriCore's technology is designed to limit the spread of infectious disease, including major public health threats of M. tuberculosis, MRSA, E.coli, Norovirus, Avian Influenza, HIV, Polio Virus, Helicobater pylori, and Legionella. PuriCore is headquartered inΒ Malvern,Β Pennsylvania, with offices inΒ Stafford,Β UK.
To receive additional information on PuriCore, please visit our website at www.puricore.com, which does not form part of this press release.
Follow the stocks
